Skip to main content

Table 2 Anti-PRP antibody response before dose 1 (pre) and one month post-dose 3 (post; ATP cohort for immunogenicity)

From: The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule

  Time point   ≥0.15 μg/mL ≥1.0 μg/mL GMC
   N % 95% CI % 95% CI Value 95% CI
DTPw-HBV/Hib 2.5 [Kft] Pre 93 44.1 33.8-54.8 9.7 4.5-17.6 0.179 0.139-0.230
  Post 93 100 96.1-100 94.6 87.9-98.2 26.71 19.161-37.23
DTPw-HBV/Hib Pre 89 42.7 32.3-53.6 10.1 4.7-18.3 0.177 0.137-0.227
  Post 89 100 95.9-100 100 95.9-100 40.75 32.301-51.40
DTPw-HBV/Hib 2.5 Pre 84 42.9 32.1-54.1 8.3 3.4-16.4 0.167 0.131-0.212
  Post 85 98.8 93.6-100 94.1 86.8-98.1 19.58 14.019-27.36
  1. N = total number of subjects; CI = confidence interval; GMC = geometric mean concentration.